Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens

Journal of the International AIDS Society

Volumn 12, Issue 1, 2009, Pages

  Doualla Bell, Florence ^a   Gaolathe, Tendani ^b,c   Avalos, Ava ^d   Cloutier, Suzanne ^d   Ndwapi, Ndwapi ^d   Holcroft, Christina ^a   Moffat, Howard ^d   Dickinson, Diana ^e   Essex, Max ^b,f   Wainberg, Mark A ^a   Mine, Madisa ^b,d  

^a MCGILL UNIVERSITY   (Canada)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c PRINCESS MARINA HOSPITAL   (Botswana)

^d Ministry of Health of Botswana   (Botswana)

^e Independence Surgery   (Botswana)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; STAVUDINE;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; ARTICLE; BOTSWANA; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; MAJOR CLINICAL STUDY; MALE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; VIRUS MUTATION;

EID: 78651441160     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-12-25     Document Type: Article

References (26)

1. WHO/UNAIDS: AIDS epidemic update 2007 [http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf].
2. Botswana National HIV/AIDS Treatment Guidelines: 2008 Version MASA Antiretroviral Therapy. Department of HIV/AIDS Prevention and Care; 2008.
3. Botswana progress report of the national report to UNGASS: Declaration of commitment on HIV/AIDS Ministry of State President-National AIDS Coordinating Agency.
4. Avalos A, Gaolathe T, Cloutier S, Ndwapi N, Doualla-Bell F, Mosepele M, Zwanila M, Moffat H, Seipone K, Wainberg M: Botswana's ART failure management: A 5-year review of the Infectious Disease Care Clinic at Princess Marina Hospital. 15th Conference on Retroviruses and Opportunistic Infections [Abstract 836]. Boston 2008.
5. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
6. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA, Quebec Primary HIV Infection Study Group: High rates of forward transmission events after acute/ early HIV-1 infection. J Infect Dis 2007, 195:951-959.
7. Doualla-Bell F, Gaseitsiwe S, Ndungú T, Modukanele M, Peter T, Novitsky V, Ndwapi N, Tendani G, Avalos A, Wester W, Bussmann H, Cardiello P, Marlink R, Moffat H, Thior I, Wainberg MA, Essex M: Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother 2004, 15:189-200.
8. Doualla-Bell F, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, Oliveira M, Moisi D, Ndwapi N, Moffat H, Essex M, Wainberg MA: High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006, 50:4182-4185.
9. Doualla-Bell F, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndwapi N, Novitsky VA, Brenner B, Oliveira M, Moisi D, Moffat H, Thior I, Essex M, Wainberg MA: Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrob Agents Chemother 2006, 50:2210-2213.
10. Kantor R: Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 2006, 19:594-606.
11. Holguín A, Paxinos E, Hertogs K, Womac C, Soriano V: Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 2004, 31:215-220.
12. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006, 20:F9-F13.
13. Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, Forbici F, Bertoli A, Alcaro S, Palamara G, d'Arminio Monforte A, Balzarini J, Antinori A, Lengauer T, Perno CF: Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 2007, 81:11507-11519.
14. Svicher V, Sing T, Santoro MM, Forbici F, Rodriguez-Barrios F, Bertoli A, Beerenwinkel N, Bellocchi MC, Gago F, d'Arminio Monforte A, Antinori A, Lengauer T, Ceccherini-Silberstein F, Perno CF: Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006, 80:7186-7198.
15. Rhee SY, Liu TF, Holmes SP, Shafer RW: HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation. PLoS Comput Biol 2007, 3(5):e87.
16. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997, 25:4876-4882.
17. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD: Update of the Drug Resistance Mutations in HIV-1: Spring 2008. Top HIV Med 2008, 16:62-68.
18. Kagan RM, Cheung PK, Huard TK, Lewinski MA: Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment. Antiviral Res 2006, 71:42-52.
19. Hosseinipour M, van Oosterhout J, Weigel R, Phiri S, Kamwendo D, Parkin N, Fiscus S, Nelson J, Eron J, Kumwenda J: The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009, 23:1127-1134.
20. Wallis CL, Bell C, Boulme R, Sanne I, Venter F, Papathanasopoulos M, Stevens W: Emerging ART Drug Resistance in Subtype C: Experience from 2 Clinics in Johannesburg, South Africa. 14th Conference of Retroviruses and Opportunistic Infections. Los Angeles, CA, USA 2007.
21. Waters L, Nelson M, Mandalia S, Bower M, Powles T, Gazzard B, Stebbing J: The risks and incidence of K65R and L74V mutations and subsequent virologic responses. Clin Infect Dis 2008, 46:96-100.
22. Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, Borroto-Esoda K, Miller MD: Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacaviror or didanosine. J Acquir Immune Defic Syndr 2007, 46:174-180.
23. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095-2106.
24. Llibre JM, Santos JR, Puig T, Molto J, Ruiz R, Clotet B: Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz [Abstract 65]. Antiv Ther 2007, 12:s74.
25. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA: Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009, 12:11.
26. Svicher V, Sing T, Santoro MM, Bertoli A, Gori C, Artese A, Alcaro S, d'Arminio Monforte A, Antinori A, Lengauer T, Perno CF, Ceccherini-Silberstein F: Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of NNRTI resistance. XV International HIV Drug Resistance Workshop [Abstract 149]. Sitges, Spain 2006.